Linked Data API

Show Search Form

Search Results

1126459
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2019-05-14
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 254164 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-21more like thismore than 2019-05-21
star this property answer text <p>It is right that these decisions are clinically led. As for any other medical treatment, if two clinicians are of the opinion that, on balance, it is not in the best interest of the patient to prescribe a cannabis-based product, then it will not be prescribed.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-21T10:45:44.23Zmore like thismore than 2019-05-21T10:45:44.23Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
star this property label Biography information for Sir Mike Penning more like this
1125623
star this property registered interest false more like this
star this property date less than 2019-05-09more like thismore than 2019-05-09
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) increase public consultation on the creation of interim guidance for medicinal cannabis and (b) ensure patient and health professional organisations are engaged in the Department’s working group on medicinal cannabis. more like this
star this property tabling member constituency Carshalton and Wallington more like this
star this property tabling member printed
Tom Brake more like this
star this property uin 252465 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-14more like thismore than 2019-05-14
star this property answer text <p>The Department does not have a standing working group on medicinal cannabis. It has, however, held a number of engagement events with representatives of patients and health professionals in relation to this policy.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to update and replace interim clinical guidelines on the prescribing of cannabis-based products for medicinal use by October 2019. NICE has consulted with a wide range of stakeholders on the draft scope of the guidelines, including a stakeholder workshop held on 6 November 2018, which was attended by patient and health professional organisations. NICE is expected to issue a public consultation on draft guidelines, which will commence in summer 2019. Anyone interested in this topic, who wants to be involved in the consultation process, can register as a stakeholder at www.nice.org.uk by searching “GID-NG10124”.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-14T15:25:08.807Zmore like thismore than 2019-05-14T15:25:08.807Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
151
star this property label Biography information for Tom Brake more like this
1124982
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department defines Naboline as a cannabis imitating rather than cannabis derived product. more like this
star this property tabling member constituency Cardiff Central more like this
star this property tabling member printed
Jo Stevens more like this
star this property uin 251364 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-13more like thismore than 2019-05-13
star this property answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 251366 more like this
star this property question first answered
less than 2019-05-13T15:38:24.053Zmore like thismore than 2019-05-13T15:38:24.053Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4425
star this property label Biography information for Jo Stevens more like this
1124983
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department is aware of any instances of (a) CBD and (b) THC being prescribed by the NHS since 1 January 2019. more like this
star this property tabling member constituency Cardiff Central more like this
star this property tabling member printed
Jo Stevens more like this
star this property uin 251365 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-13more like thismore than 2019-05-13
star this property answer text <p>The published data shows that the following number of items of Nabilone (a synthetic product which mimics tetrahydrocannabinol (THC)) and Sativex (a product containing natural THC and cannabidiol (CBD)) were dispensed in January and February 2019.</p><p> </p><table><tbody><tr><td><p> </p></td><td colspan="2"><p>Number of prescription items</p></td></tr><tr><td><p> </p></td><td><p>January 2019</p></td><td><p>February 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>44</p></td><td><p>36</p></td></tr><tr><td><p>Sativex</p></td><td><p>167</p></td><td><p>159</p></td></tr></tbody></table><p> </p><p>Data, from the NHS Business Services Authority for January and February 2019, suggest that three National Health Service prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. Additionally, the NHS Business Services Authority data report that 10 private prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in January and February 2019.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-13T16:07:00.07Zmore like thismore than 2019-05-13T16:07:00.07Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4425
star this property label Biography information for Jo Stevens more like this
1124984
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, when (a) Naboline and (b) Savitex were first made available to prescribe on the NHS. more like this
star this property tabling member constituency Cardiff Central more like this
star this property tabling member printed
Jo Stevens more like this
star this property uin 251366 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-13more like thismore than 2019-05-13
star this property answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 251364 more like this
star this property question first answered
less than 2019-05-13T15:38:24.097Zmore like thismore than 2019-05-13T15:38:24.097Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4425
star this property label Biography information for Jo Stevens more like this
1123519
star this property registered interest false more like this
star this property date less than 2019-04-29more like thismore than 2019-04-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the timeframe is for the process evaluation being undertaken by the NHS on prescribing cannabis-based products for medical use; and if he will he make a statement. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 248610 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-08more like thismore than 2019-05-08
star this property answer text <p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.</p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 248611 more like this
star this property question first answered
less than 2019-05-08T13:57:42.103Zmore like thismore than 2019-05-08T13:57:42.103Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
star this property label Biography information for Sir Mike Penning more like this
1123520
star this property registered interest false more like this
star this property date less than 2019-04-29more like thismore than 2019-04-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, who he will be engaging with in the process evaluation on prescribing cannabis-based products for medical use. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 248611 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-08more like thismore than 2019-05-08
star this property answer text <p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.</p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 248610 more like this
star this property question first answered
less than 2019-05-08T13:57:42.167Zmore like thismore than 2019-05-08T13:57:42.167Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
star this property label Biography information for Sir Mike Penning more like this
1123521
star this property registered interest false more like this
star this property date less than 2019-04-29more like thismore than 2019-04-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how the National Institute for Health Research will identify patients with severe intractable epilepsy to use as a placebo in research into the safety and clinical efficacy and effectiveness of cannabis-based products for medical use in humans. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 248612 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-08more like thismore than 2019-05-08
star this property answer text <p>To stimulate research proposals, the National Institute for Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the United Kingdom market.</p><p>The NIHR also remain open to the submission of proposals outside of these specific calls. Proposals made to NIHR are assessed for scientific rigour, which will include the design of the trials, before funding is allocated to the applicants.</p><p>The process for selecting people for inclusion in any trials will be determined by the researchers and will be dependent on the study design used in the trial.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-08T13:59:06.047Zmore like thismore than 2019-05-08T13:59:06.047Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
star this property label Biography information for Sir Mike Penning more like this
1123443
star this property registered interest false more like this
star this property date less than 2019-04-26more like thismore than 2019-04-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, how the system of second opinions on the prescribing of medical cannabis oil will be organised; and if he will make a statement. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 247998 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-07more like thismore than 2019-05-07
star this property answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 247999 more like this
star this property question first answered
less than 2019-05-07T16:43:13.763Zmore like thismore than 2019-05-07T16:43:13.763Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
star this property label Biography information for Sir Mike Penning more like this
1123444
star this property registered interest false more like this
star this property date less than 2019-04-26more like thismore than 2019-04-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, who will be responsible for offering patients a second opinion on prescribing medical cannabis oil. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 247999 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-07more like thismore than 2019-05-07
star this property answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 247998 more like this
star this property question first answered
less than 2019-05-07T16:43:13.81Zmore like thismore than 2019-05-07T16:43:13.81Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
star this property label Biography information for Sir Mike Penning more like this